Myasthenia Gravis Disease Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class (IVIg, Monoclonal Antibodies, Immunosuppressants, Cholinesterase Inhibitors, Corticosteroids); By Diagnosis, By Treatment, By Distribution Channel; By Region; Segment Forecast, 2024 - 2032
The global myasthenia gravis disease treatment market size is expected to reach USD 2.32 billion by 2032, according to a new study by Polaris Market Research. The report “Myasthenia Gravis Disease Market Share, Size, Trends, Industry Analysis Report, By Drug Class (IVIg, Monoclonal Antibodies, Immunosuppressants, Cholinesterase Inhibitors, Corticosteroids); By Diagnosis, By Treatment, By Distribution Channel; By Region; Segment Forecast, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Myasthenia gravis is an autoimmune neuromuscular disorder that causes muscle weakness and fatigue due to the immune system attacking the connection between nerves and muscles.
The market for treating Myasthenia Gravis (MG) has been growing steadily in recent years due to several factors. There has been an increase in the number of diagnoses, better understanding of the disease, and advancements in treatment options. Pharmaceutical companies have also invested in research and development to introduce innovative therapies that offer more effectiveness and fewer side effects. With the emergence of biologics and targeted therapies, the demand for safer and more efficient treatments is expected to continue driving the growth of the global MG treatment market.
The COVID-19 pandemic had a significant impact on the Myasthenia Gravis (MG) disease market. MG faced challenges due to the healthcare system's focus on COVID-19 patients, causing delays in diagnosis and treatment. However, the pandemic accelerated the use of telemedicine and remote monitoring, which provided crucial tools for MG patients to consult with healthcare providers while minimizing virus exposure. The pharmaceutical industry continued to develop novel therapies for MG despite disruptions, offering hope for improved treatment options.
Additionally, a study published in the National Library of Medicine in June 2021 highlighted the significant impact of coronary artery disease (CAD) on global health. CAD alone is responsible for approximately 610,000 deaths annually, accounting for an estimated one in four deaths and making it the foremost cause of mortality in the United States. With the incidence of CAD rising, there is a growing demand for effective coronary stent devices to address this pressing medical need. Consequently, this factor is projected to drive the demand for coronary stents throughout the forecast period.
Myasthenia Gravis Disease Market Report Highlights
In 2022, the IVIg segment held the largest revenue share in the myasthenia gravis disease market. Intravenous Immunoglobulin (IVIg) treatment involves the infusion of immunoglobulin antibodies obtained from healthy donors. This medical procedure has been found to be highly effective in temporarily regulating the immune system and managing the symptoms of Myasthenia Gravis (MG).
The hospital segment accounted for the highest market share during the forecast period. Hospital pharmacies play a vital role in managing Myasthenia Gravis (MG) through the distribution and application of various medications. As MG cases increase, more patients seek treatment in hospitals, leading to a higher demand for MG-specific drugs in hospital pharmacies.
In 2022, North America dominated the largest market. Myasthenia gravis (MG) exhibits a significant prevalence in North America, positioning it as a key player in the landscape of treatment. The region's robust healthcare infrastructure facilitates the identification and management of a substantial number of MG cases, drawing the interest of pharmaceutical firms and researchers alike. Furthermore, the resilient healthcare reimbursement framework effectively extends coverage to numerous costly MG treatments, enhancing their accessibility for patients and promoting prompt intervention.
The Asia-Pacific region accounted for the fastest growth in the myasthenia disease treatment market. The market's growth is driven by various factors, notably the concerted efforts of both public and private entities. These endeavors primarily focus on advancing and distributing effective treatments for neuromuscular disorders. Moreover, the market's expansion is fueled by increasing public awareness of neuromuscular conditions, supported by educational campaigns and information dissemination initiatives.
The global key market players include AbbVie Inc., Alexion Pharmaceuticals, Inc., Bausch Health Companies Inc., Bristol-Myers Squibb Company, Grifols, S.A., Mylan N.V., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holdings AG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd.
Polaris Market Research has segmented the myasthenia disease treatment market report based on drug class, diagnosis, treatment, distribution channel, and region:
Myasthenia Gravis Disease Treatment, Drug Class Outlook (Revenue - USD Billion, 2019 - 2032)
IVIg
Monoclonal Antibodies
Immunosuppressants
Cholinesterase Inhibitors
Corticosteroids
Myasthenia Gravis Disease Treatment, Diagnosis Outlook (Revenue - USD Billion, 2019 - 2032)
Blood Tests
Electrodiagnosis
Edrophonium Test
Myasthenia Gravis Disease Treatment, Treatment Outlook (Revenue - USD Billion, 2019 - 2032)
Surgery
Medication
HSCT
Myasthenia Gravis Disease Treatment, Distribution Channel Outlook (Revenue - USD Billion, 2019 - 2032)
Online Pharmacies
Hospital Pharmacies
Retail Pharmacies
Myasthenia Gravis Disease Treatment, Regional Outlook (Revenue - USD Billion, 2019 - 2032)
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Latin America
Argentina
Brazil
Mexico
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
- 1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
- 2. Executive Summary
- 2.1. Market Highlights
- 3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
- 4. Global Myasthenia Gravis Disease Treatment Market Insights
- 4.1. Myasthenia Gravis Disease Treatment – Industry Snapshot
- 4.2. Myasthenia Gravis Disease Treatment Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Improvement in therapies and treatment options across the Globe will Facilitate market growth
- 4.2.1.2. Inflation of healthcare infrastructure bill bolster market growth
- 4.2.2. Restraints and Challenges
- 4.2.2.1. High treatment cost will hamper on the market growth
- 4.3. Porter’s Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTLE Analysis
- 4.5. Myasthenia Gravis Disease Treatment Industry Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
- 5. Global Myasthenia Gravis Disease Treatment Market, by Drug Class
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
- 5.3. IVIg
- 5.3.1. Global Myasthenia Gravis Disease Treatment Market, by IVIg, by Region, 2019-2032 (USD Billion)
- 5.4. Monoclonal Antibodies
- 5.4.1. Global Myasthenia Gravis Disease Treatment Market, by Monoclonal Antibodies, by Region, 2019-2032 (USD Billion)
- 5.5. Immunosuppressants
- 5.5.1. Global Myasthenia Gravis Disease Treatment Market, by Immunosuppressants, by Region, 2019-2032 (USD Billion)
- 5.6. Cholinesterase Inhibitors
- 5.6.1. Global Myasthenia Gravis Disease Treatment Market, by Cholinesterase Inhibitors, by Region, 2019-2032 (USD Billion)
- 5.7. Corticosteroids
- 5.7.1. Global Myasthenia Gravis Disease Treatment Market, by Corticosteroids, by Region, 2019-2032 (USD Billion)
- 6. Global Myasthenia Gravis Disease Treatment Market, by Diagnosis
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
- 6.3. Blood Tests
- 6.3.1. Global Myasthenia Gravis Disease Treatment Market, by Blood Tests, by Region, 2019-2032 (USD Billion)
- 6.4. Electrodiagnosis
- 6.4.1. Global Myasthenia Gravis Disease Treatment Market, by Electrodiagnosis, by Region, 2019-2032 (USD Billion)
- 6.5. Edrophonium Test
- 6.5.1. Global Myasthenia Gravis Disease Treatment Market, by Edrophonium Test, by Region, 2019-2032 (USD Billion)
- 7. Global Myasthenia Gravis Disease Treatment Market, by Treatment
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 7.3. Surgery
- 7.3.1. Global Myasthenia Gravis Disease Treatment Market, by Surgery, by Region, 2019-2032 (USD Billion)
- 7.4. Medication
- 7.4.1. Global Myasthenia Gravis Disease Treatment Market, by Medication, by Region, 2019-2032 (USD Billion)
- 7.5. HSCT
- 7.5.1. Global Myasthenia Gravis Disease Treatment Market, by HSCT, by Region, 2019-2032 (USD Billion)
- 8. Global Myasthenia Gravis Disease Treatment Market, by Distribution Channel
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Global Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.3. Online Pharmacies
- 8.3.1. Global Myasthenia Gravis Disease Treatment Market, by Online Pharmacies, by Region, 2019-2032 (USD Billion)
- 8.4. Hospital Pharmacies
- 8.4.1. Global Myasthenia Gravis Disease Treatment Market, by Hospital Pharmacies, by Region, 2019-2032 (USD Billion)
- 8.5. Retail Pharmacies
- 8.5.1. Global Myasthenia Gravis Disease Treatment Market, by Retail Pharmacies, by Region, 2019-2032 (USD Billion)
- 9. Global Myasthenia Gravis Disease Treatment Market, by Geography
- 9.1. Key findings
- 9.2. Introduction
- 9.2.1. Myasthenia Gravis Disease Treatment Market Assessment, By Geography, 2019-2032 (USD Billion)
- 9.3. Myasthenia Gravis Disease Treatment Market – North America
- 9.3.1. North America: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
- 9.3.2. North America: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.3.3. North America: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
- 9.3.4. North America: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.3.5. Myasthenia Gravis Disease Treatment Market – U.S.
- 9.3.5.1. U.S.: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
- 9.3.5.2. U.S.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.3.5.3. U.S.: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
- 9.3.5.4. U.S.: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.3.6. Myasthenia Gravis Disease Treatment Market – Canada
- 9.3.6.1. Canada: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
- 9.3.6.2. Canada: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.3.6.3. Canada: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
- 9.3.6.4. Canada: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.4. Myasthenia Gravis Disease Treatment Market – Europe
- 9.4.1. Europe: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
- 9.4.2. Europe: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.4.3. Europe: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
- 9.4.4. Europe: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.4.5. Myasthenia Gravis Disease Treatment Market – UK
- 9.4.5.1. UK: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
- 9.4.5.2. UK: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.4.5.3. UK: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
- 9.4.5.4. UK: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.4.6. Myasthenia Gravis Disease Treatment Market – France
- 9.4.6.1. France: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
- 9.4.6.2. France: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.4.6.3. France: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
- 9.4.6.4. France: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.4.7. Myasthenia Gravis Disease Treatment Market – Germany
- 9.4.7.1. Germany: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
- 9.4.7.2. Germany: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.4.7.3. Germany: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
- 9.4.7.4. Germany: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.4.8. Myasthenia Gravis Disease Treatment Market – Italy
- 9.4.8.1. Italy: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
- 9.4.8.2. Italy: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.4.8.3. Italy: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
- 9.4.8.4. Italy: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.4.9. Myasthenia Gravis Disease Treatment Market – Spain
- 9.4.9.1. Spain: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
- 9.4.9.2. Spain: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.4.9.3. Spain: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
- 9.4.9.4. Spain: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.4.10. Myasthenia Gravis Disease Treatment Market – Netherlands
- 9.4.10.1. Netherlands: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
- 9.4.10.2. Netherlands: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.4.10.3. Netherlands: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
- 9.4.10.4. Netherlands: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.4.11. Myasthenia Gravis Disease Treatment Market – Russia
- 9.4.11.1. Russia: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
- 9.4.11.2. Russia.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.4.11.3. Russia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
- 9.4.11.4. Russia: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.5. Myasthenia Gravis Disease Treatment Market – Asia Pacific
- 9.5.1. Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
- 9.5.2. Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.5.3. Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
- 9.5.4. Asia Pacific: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.5.5. Myasthenia Gravis Disease Treatment Market – China
- 9.5.5.1. China: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
- 9.5.5.2. China.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.5.5.3. China: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
- 9.5.5.4. China: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.5.6. Myasthenia Gravis Disease Treatment Market – India
- 9.5.6.1. India: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
- 9.5.6.2. India.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.5.6.3. India: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
- 9.5.6.4. India: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.5.7. Myasthenia Gravis Disease Treatment Market – Japan
- 9.5.7.1. Japan: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
- 9.5.7.2. Japan.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.5.7.3. Japan: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
- 9.5.7.4. Japan: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.5.8. Myasthenia Gravis Disease Treatment Market – Malaysia
- 9.5.8.1. Malaysia: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
- 9.5.8.2. Malaysia.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.5.8.3. Malaysia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
- 9.5.8.4. Malaysia: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.5.9. Myasthenia Gravis Disease Treatment Market – Indonesia
- 9.5.9.1. Indonesia: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
- 9.5.9.2. Indonesia.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.5.9.3. Indonesia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
- 9.5.9.4. Indonesia: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.5.10. Myasthenia Gravis Disease Treatment Market – South Korea
- 9.5.10.1. South Korea: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
- 9.5.10.2. South Korea.: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.5.10.3. South Korea: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
- 9.5.10.4. South Korea: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.6. Myasthenia Gravis Disease Treatment Market – Middle East & Africa
- 9.6.1. Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
- 9.6.2. Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.6.3. Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
- 9.6.4. Middle East & Africa: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.6.5. Myasthenia Gravis Disease Treatment Market – Saudi Arabia
- 9.6.5.1. Saudi Arabia: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
- 9.6.5.2. Saudi Arabia: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.6.5.3. Saudi Arabia: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
- 9.6.5.4. Saudi Arabia: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.6.6. Myasthenia Gravis Disease Treatment Market – South Africa
- 9.6.6.1. South Africa: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
- 9.6.6.2. South Africa: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.6.6.3. South Africa: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
- 9.6.6.4. South Africa: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.6.7. Myasthenia Gravis Disease Treatment Market – Israel
- 9.6.7.1. Israel: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
- 9.6.7.2. Israel: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.6.7.3. Israel: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
- 9.6.7.4. Israel: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.6.8. Myasthenia Gravis Disease Treatment Market – UAE
- 9.6.8.1. UAE: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
- 9.6.8.2. UAE: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.6.8.3. UAE: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
- 9.6.8.4. UAE: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.7. Myasthenia Gravis Disease Treatment Market – Latin America
- 9.7.1. Latin America: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
- 9.7.2. Latin America: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.7.3. Latin America: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
- 9.7.4. Latin America: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.7.5. Myasthenia Gravis Disease Treatment Market – Mexico
- 9.7.5.1. Mexico: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
- 9.7.5.2. Mexico: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.7.5.3. Mexico: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
- 9.7.5.4. Mexico: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.7.6. Myasthenia Gravis Disease Treatment Market – Brazil
- 9.7.6.1. Brazil: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
- 9.7.6.2. Brazil: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.7.6.3. Brazil: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
- 9.7.6.4. Brazil: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 9.7.7. Myasthenia Gravis Disease Treatment Market – Argentina
- 9.7.7.1. Argentina: Myasthenia Gravis Disease Treatment Market, by Drug Class, 2019-2032 (USD Billion)
- 9.7.7.2. Argentina: Myasthenia Gravis Disease Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.7.7.3. Argentina: Myasthenia Gravis Disease Treatment Market, by Diagnosis, 2019-2032 (USD Billion)
- 9.7.7.4. Argentina: Myasthenia Gravis Disease Treatment Market, by Treatment, 2019-2032 (USD Billion)
- 10. Competitive Landscape
- 10.1. Expansion and Acquisition Analysis
- 10.1.1. Expansion
- 10.1.2. Acquisitions
- 10.2. Partnerships/Collaborations/Agreements/Exhibitions
- 11. Company Profiles
- 11.1. AbbVie Inc.
- 11.1.1. Company Overview
- 11.1.2. Financial Performance
- 11.1.3. Product Benchmarking
- 11.1.4. Recent Development
- 11.2. Alexion Pharmaceuticals, Inc.
- 11.2.1. Company Overview
- 11.2.2. Financial Performance
- 11.2.3. Product Benchmarking
- 11.2.4. Recent Development
- 11.3. Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals)
- 11.3.1. Company Overview
- 11.3.2. Financial Performance
- 11.3.3. Product Benchmarking
- 11.3.4. Recent Development
- 11.4. Bristol-Myers Squibb Company (now part of Bristol Myers Squibb)
- 11.4.1. Company Overview
- 11.4.2. Financial Performance
- 11.4.3. Product Benchmarking
- 11.4.4. Recent Development
- 11.5. Grifols, S.A.
- 11.5.1. Company Overview
- 11.5.2. Financial Performance
- 11.5.3. Product Benchmarking
- 11.5.4. Recent Development
- 11.6. Mylan N.V. (now part of Viatris Inc.)
- 11.6.1. Company Overview
- 11.6.2. Financial Performance
- 11.6.3. Product Benchmarking
- 11.6.4. Recent Development
- 11.7. Novartis AG
- 11.7.1. Company Overview
- 11.7.2. Financial Performance
- 11.7.3. Product Benchmarking
- 11.7.4. Recent Development
- 11.8. Pfizer Inc.
- 11.8.1. Company Overview
- 11.8.2. Financial Performance
- 11.8.3. Product Benchmarking
- 11.8.4. Recent Development
- 11.9. Regeneron Pharmaceuticals, Inc.
- 11.9.1. Company Overview
- 11.9.2. Financial Performance
- 11.9.3. Product Benchmarking
- 11.9.4. Recent Development
- 11.10. Roche Holdings AG (including its subsidiary, Genentech)
- 11.10.1. Company Overview
- 11.10.2. Financial Performance
- 11.10.3. Product Benchmarking
- 11.10.4. Recent Development
- 11.11. Takeda Pharmaceutical Company Limited
- 11.11.1. Company Overview
- 11.11.2. Financial Performance
- 11.11.3. Product Benchmarking
- 11.11.4. Recent Development
- 11.12. Teva Pharmaceutical Industries Ltd.
- 11.12.1. Company Overview
- 11.12.2. Financial Performance
- 11.12.3. Product Benchmarking
- 11.12.4. Recent Development
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook